VE-416 / Vedanta Biosci - LARVOL DELTA

VE416 for Treatment of Food Allergy (clinicaltrials.gov) - P1/2 | N=60 | Recruiting | Sponsor: Massachusetts General Hospital | Trial primary completion date: Jun 2023 ➔ Nov 2023

Trial primary completion date • Allergy • Food Hypersensitivity • Immunology

VE416 for Treatment of Food Allergy (clinicaltrials.gov) - P1/2 | N=60 | Recruiting | Sponsor: Massachusetts General Hospital | Trial primary completion date: Jan 2023 ➔ Jun 2023

Trial primary completion date • Allergy • Food Hypersensitivity • Immunology

VE416 for Treatment of Food Allergy (clinicaltrials.gov) - P1/2 | N=60 | Recruiting | Sponsor: Massachusetts General Hospital | Trial completion date: Dec 2022 ➔ Jan 2024 | Trial primary completion date: Dec 2021 ➔ Jan 2023

Trial completion date • Trial primary completion date • Allergy • Food Hypersensitivity • Immunology

Vedanta Biosciences Completes $68 Million Series D Financing (Businesswire) - "Vedanta Biosciences...announced the closing of a $68 million Series D financing and provided a pipeline update....A Phase 1/2, investigator-sponsored clinical study is underway at Massachusetts General Hospital, exploring use of VE416 both as a monotherapy and in combination with an oral peanut immunotherapy over the course of several months....Topline data from the Phase 1/2 clinical trial is expected to be reported in 2022, subject to investigator timelines."

Financing • P1/2 data • Food Hypersensitivity

VE416 for Treatment of Food Allergy (clinicaltrials.gov) - P1/2; N=60; Recruiting; Sponsor: Massachusetts General Hospital; N=40 ➔ 60; Trial completion date: Jul 2021 ➔ Dec 2022; Trial primary completion date: Jul 2020 ➔ Dec 2021

Enrollment change • Trial completion date • Trial primary completion date • Allergy • Food Hypersensitivity • Immunology

PureTech Announces Annual Results for Year Ended December 31, 2020 (Businesswire) - "We are planning registration-enabling studies of LYT-100 for the treatment of idiopathic pulmonary fibrosis, or IPF, and potentially other progressive fibrosing interstitial lung diseases, or PF-ILDs, and we expect to provide additional guidance later this year...Topline results from a Phase 1/2 trial of VE416 for food allergy are expected in 2022."

New trial • P1/2 data • Food Hypersensitivity • Idiopathic Pulmonary Fibrosis

"At #FAFSummit19, ⁦@WayneShreffler⁩ discussing the clinical study he leads at MGH with ⁦@VedantaBio⁩ ‘s VE416 in adults and teenagers with peanut allergies #microbiome" (@bernatolle)

Clinical